“Plus, we are in discussions with several additional primary care practices with over fifty (50) providers that will provide access to an additional 150,000 patients who may benefit from clinical research opportunities.”
That all sounds great. Hopefully the deal comes to fruition.
Question is at what cost and how is it to be financed? Is Regentys still a part of Gnbt? They are never noted.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links